RxDoctor Payments DataLook up a doctor →

Richard Rubin, MD

Cardiovascular Disease · Chevy Chase, MDNPI 1962478578

Payments from drug & device makers

$41,699in general payments, 2019–2025

Across 483 payments — averaging $86.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$18K
  • E.r. Squibb & Sons, L.L.C.$9K
  • AstraZeneca$4K
  • Amgen$1K
  • Abbott$905
  • Novartis$773
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$4,46811%
  • Speaking & faculty fees$22,85055%
  • Travel & lodging$5871%
  • Food & beverage$13,65833%
  • Education$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,699 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$486,345
Medicare patients
1,199
Services billed
6,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$433,607
XareltoRivaroxaban102$139,227
EntrestoSacubitril/Valsartan27$38,939
Repatha SureclickEvolocumab20$23,140
MultaqDronedarone Hcl12$22,943
BrilintaTicagrelor12$16,017
Metoprolol Succinate461$10,846
LivaloPitavastatin Calcium11$10,301
Telmisartan217$9,438
Flecainide Acetate139$9,213
Rosuvastatin Calcium313$7,759
EdarbiAzilsartan Medoxomil16$7,191
Dabigatran EtexilateDabigatran Etexilate Mesylate18$6,256
Nebivolol Hcl85$5,667
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid56$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17,746$433,607339 claims
Johnson & JohnsonXarelto$478$139,227102 claims
NovartisEntresto$773$38,93927 claims
Sanofi-aventis U.S. LLCMultaq$455$22,94312 claims
AstraZenecaBrilinta$4,252$16,01712 claims
Arbor Pharmaceuticals, Inc.Edarbi$27$7,19116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →